Global Oil Price Surges Over 1% as US-Iran Conflict Escalates, Exacerbating Negotiation Uncertainty
BlockBeats News, June 3rd, influenced by the escalating US-Iran tensions and uncertain negotiation prospects, international oil prices rose on Wednesday. In particular, WTI crude oil futures for July delivery rose over 1% to $94.81 per barrel, and Brent crude oil futures for August delivery rose by 0.88% to $96.84 per barrel.
The US Central Command stated that the US military shot down multiple Iranian missiles and drones, and conducted defensive strikes against Iranian targets. Meanwhile, Trump and US Secretary of State Pompeo stated that US-Iran negotiations are still ongoing, with Iran potentially willing to negotiate certain aspects of its nuclear program. However, Iranian media had previously reported a lack of communication between the two sides for several days and suggested that Tehran might consider seeking a complete closure of the Strait of Hormuz.
Fitch Group analysts pointed out that the US-Iran conflict has caused significant damage to the Middle East oil and gas industry, with billions of dollars in losses due to disrupted exports, production shutdowns, and repeated attacks on infrastructure, with Qatar, Bahrain, and Iraq experiencing the most severe impact.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
